Balkees Abderrahman is Postdoctoral Fellow, Breast Medical Oncology, University of Texas MD Anderson Cancer Center, 1500 Holcombe Blvd. Unit #1354, Houston, TX 77030, United States.
Breast cancer prevention trumps cureSubscription
Breast cancer is the most prevalent female cancer and is estimated to increase by 50% by 2030 compared to the incidence in 2011. The decision by the National Institute for Health and Care Excellence (NICE), the UK health technology appraiser, to recommend the use of preventive medicines, which are known to decrease the risk of developing breast cancer, is a welcome advance in public health. These medicines have been rigorously studied, and tens of thousands of women who at high risk of
Since the dawn of hormonal replacement therapy — now known as menopausal hormone therapy — there have been conflicting reports about its risks and safety. A thorough examination of the evidence suggests it can be used safely in menopausal women.
Long-term (five years) adjuvant tamoxifen treatment for oestrogen receptor-positive, or ER-positive, breast cancer post-surgery is recognised as a major advance in healthcare. Clinical trials comparing standard and extended tamoxifen therapy found a major decrease in mortality occurred in the ten years following a decade of adjuvant therapy. Studies in premenopausal breast cancer patients showed that ovarian function suppression (OFS) plus an aromatase inhibitor (AI), such as